Barclays Downgrades MRK.US to Hold Rating, Raises Target Price

Barclays has downgraded Merck & Co (MRK.US) to a hold rating, according to an analyst from Barclays. The target price for MRK.US has been raised from $150 to $174.46.

The analyst, Emily Field, has a success rate of 46.0% and an average return of 2.1% over the past year, based on data from TipRanks.

TipRanks is an independent third-party service that provides analysis data from financial analysts and calculates their success rates and average returns.